Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
Patients in fluctuating stages of Parkinson’s disease (PD) require device-aided treatments. Continuous infusion of levodopa–carbidopa intestinal gel (LCIG) is a well-proven option in clinical practice. We now report the first clinical experience of levodopa–entacapone–carbidopa intestinal gel (LECIG...
Main Authors: | Mezin Öthman, Erik Widman, Ingela Nygren, Dag Nyholm |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/4/254 |
Similar Items
-
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01) -
USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01) -
Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01) -
Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01) -
Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)